Compare FUN & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUN | PHVS |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2023 | 2020 |
| Metric | FUN | PHVS |
|---|---|---|
| Price | $19.98 | $26.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 11 |
| Target Price | $23.92 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 1.6M | 186.6K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,100,289,000.00 | N/A |
| Revenue This Year | $4.76 | N/A |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.45 | N/A |
| 52 Week Low | $12.51 | $12.01 |
| 52 Week High | $38.27 | $29.85 |
| Indicator | FUN | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 45.76 |
| Support Level | $14.85 | $24.55 |
| Resistance Level | $27.37 | $28.72 |
| Average True Range (ATR) | 0.96 | 1.38 |
| MACD | 0.29 | -0.03 |
| Stochastic Oscillator | 92.44 | 32.65 |
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS. The parks are family-oriented, with recreational facilities for people of all ages, and provide clean and attractive environments with exciting rides and immersive entertainment. The Company generates revenue from sales of admission to the amusement parks and water parks, from purchases of food, merchandise and games both inside and outside the parks, from the sale of accommodations and other extra-charge.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.